Why the study?
Does bivalirudin reduce circuit-related thrombotic events and blood product administration compared to heparin in patients requiring venovenous extracorporeal membrane oxygenation?
Does bivalirudin reduce circuit-related thrombotic events and blood product administration compared to heparin in patients requiring venovenous extracorporeal membrane oxygenation?
Bivalirudin may offer a safer and more effective anticoagulation profile than heparin for patients on venovenous ECMO by reducing circuit thrombosis and blood product requirements.
Answers are grounded in this paper and cite their sources.
Bivalirudin was associated with fewer thrombotic events and transfusions in VV-ECMO; hypothesis-generating and leaves open need for RCTs.
Patients receiving bivalirudin for systemic anticoagulation on venovenous extracorporeal membrane oxygenation experienced a decrease in the number of extracorporeal membrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered.
No takes yet. Share an insight, caveat, or question.
Rivosecchi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: